F S&P 500
5,308.50 +13.00 (+0.25%) F Dow Jones
38,892.00 +101.00 (+0.26%) F Nasdaq
18,628.75 +37.75 (+0.20%) E-mini Russell 2000 Index Futur
2,086.30 +10.50 (+0.51%) Petróleo
76.75 -0.24 (-0.31%) Oro
2,344.80 -1.00 (-0.04%)
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc.
8285 El Rio
Suite 190
Houston, TX 77054
United States
346 396 4770
https://www.nuot.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. David E. Jorden CPA | CEO, CFO, Secretary & Executive Director | 225k | N/D | 1962 |
| Dr. Peter Anton Clausen Ph.D. | COO & Chief Scientific Officer | 225k | N/D | 1966 |
| Mr. Joseph A. Del Guercio | Informal Board Advisor | 27.5k | N/D | 1972 |
Descripción
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Nuo Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
